Form 4 for ABT Abbott Laboratories
Accepted 2022-02-23 00:00:00 ET · period of report 2022-02-18 · accession 0001415889-22-001742 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-23 | 2022-02-18 | ABT | Moreland Mary K | EVP | A - Grant | $0.00 | +15.8K | 88.2K | +22% | $0 |
| D | 2022-02-23 | 2022-02-22 | ABT | Moreland Mary K | EVP | F - Tax | $116.79 | -793 | 87.4K | -0.9% | -$92.6K |
| D | 2022-02-23 | 2021-02-22 | ABT | Moreland Mary K | EVP | S - Sale | $119.31 | -400 | 87.0K | -0.5% | -$47.7K |
| D | 2022-02-23 | 2022-02-18 | ABT | Moreland Mary K | EVP | A - Grant | $0.00 | +73.7K | 73.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2022-02-18 | A | A | 15,813 | $0.00 | 88,158 | D | — | — | (F1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. |
| 2 | Common | Common shares without par value | 2022-02-22 | F | D | 793 | $116.79 | 87,365 | D | — | — | |
| 3 | Common | Common shares without par value | 2021-02-22 | S | D | 400 | $119.31 | 86,965 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4 | Derivative | Option (right to buy) | 2022-02-18 | A | A | 73,696 | $0.00 | 73,696 | D | $117.58 · 2023-02-18 to 2032-02-17 | 73,696 Common Shares | (F4) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025. |